Self-Delivery Photodynamic Re-educator Enhanced Tumor Treatment by Inducing Immunogenic Cell Death and Improving Immunosuppressive Microenvironments
Source abstract
Abstract
Immunotherapy is known to be a promising strategy in the clinical treatment of malignant tumors, but it has received generally low response rates in various tumors because of the poor immunogenicity and multiple immunosuppressive microenvironments. A self-delivery photodynamic re-educator, denoted as CCXB, is synthesized through the self-assembly of chlorine e6 (Ce6) and celecoxib (CXB). As a carrier-free nanomedicine, CCXB shows a high drug loading rate, improved water stability, superior cellular uptake, and tumor accumulation capability. In comparison with free Ce6, CCXB triggers much stronger photodynamic therapy (PDT) to reduce the proliferation of breast cancer cells and activates robust immune responses via the induction of immunogenic cell death (ICD). Better yet, CXB-mediated cyclooxygenase 2 (COX-2) inhibition can decrease the level of synthesis of prostaglandin E2 (PGE2) to further improve immunosuppressive microenvironments. With the increase of cytotoxic T lymphocytes (CTLs) and decrease of regulatory T cells (Tregs) in tumor, in vivo antitumor immunity is significantly amplified to inhibit the metastasis of breast cancer. This study sheds light on developing drug codelivery systems with collaborative mechanisms for immunotherapy of metastatic tumors.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Biomedical Engineering & Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering, Southern Medical University, Guangzhou 510515, P. R. China
Funding
Basic and Applied Basic Research Foundation of Guangdong Province · National Natural Science Foundation of China
References (33)
Show source-provided references
1. 10.3390/medicina5601001510.3390/medicina56010015 ↗
2. 10.1038/onc.2008.27110.1038/onc.2008.271 ↗
3. 10.1016/j.cub.2020.06.08110.1016/j.cub.2020.06.081 ↗
4. 10.3389/fonc.2019.0154010.3389/fonc.2019.01540 ↗
5. 10.1158/0008-5472.CAN-18-396210.1158/0008-5472.CAN-18-3962 ↗
6. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
7. 10.1038/nri254510.1038/nri2545 ↗
8. 10.3389/fimmu.2017.0055510.3389/fimmu.2017.00555 ↗
9. 10.1038/cddis.2013.20710.1038/cddis.2013.207 ↗
10. 10.7150/thno.3842510.7150/thno.38425 ↗
11. 10.1021/acs.nanolett.9b0230610.1021/acs.nanolett.9b02306 ↗
12. 10.1021/acs.nanolett.9b0057910.1021/acs.nanolett.9b00579 ↗
13. 10.1021/jp070629p10.1021/jp070629p ↗
14. 10.1039/C8CS00896E10.1039/C8CS00896E ↗
15. 10.1002/adma.20190296010.1002/adma.201902960 ↗
16. 10.1158/0008-5472.CAN-20-275610.1158/0008-5472.CAN-20-2756 ↗
17. 10.1021/acsnano.3c0089110.1021/acsnano.3c00891 ↗
18. 10.1002/adhm.20190130710.1002/adhm.201901307 ↗
19. 10.1016/j.ccell.2015.03.00110.1016/j.ccell.2015.03.001 ↗
20. 10.1016/j.jconrel.2018.12.01410.1016/j.jconrel.2018.12.014 ↗
21. 10.1016/j.canlet.2016.05.02310.1016/j.canlet.2016.05.023 ↗
22. 10.1016/j.jconrel.2017.08.01910.1016/j.jconrel.2017.08.019 ↗
23. 10.1007/s40005-017-0370-410.1007/s40005-017-0370-4 ↗
24. 10.1096/fj.01-0299fje10.1096/fj.01-0299fje ↗
25. 10.1007/s40005-017-0382-010.1007/s40005-017-0382-0 ↗
26. 10.1016/j.addr.2017.02.00210.1016/j.addr.2017.02.002 ↗
27. 10.1016/j.addr.2018.03.00710.1016/j.addr.2018.03.007 ↗
28. 10.2174/138161203345405410.2174/1381612033454054 ↗
29. 10.1016/S1471-4914(02)00011-410.1016/S1471-4914(02)00011-4 ↗
30. 10.1038/nrd103410.1038/nrd1034 ↗
31. 10.2353/ajpath.2010.09060710.2353/ajpath.2010.090607 ↗
32. 10.1016/j.cell.2015.08.01510.1016/j.cell.2015.08.015 ↗
33. 10.1002/adma.20180332210.1002/adma.201803322 ↗